Vanguard Group Inc Prelude Therapeutics Inc Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,009,204 shares of PRLD stock, worth $898,191. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,009,204
Previous 1,010,392
0.12%
Holding current value
$898,191
Previous $1.28 Million
39.44%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PRLD
# of Institutions
56Shares Held
28.3MCall Options Held
23.9KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$9.71 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$9.01 Million0.09% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$951,3350.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD976KShares$868,7700.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny657KShares$584,4630.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $32.4M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...